Valor de la respuesta virologica precoz como factor predictivo de respuesta virologica sostenida al tratamiento con interferon alfa-2b y ribavirina en pacientes con hepatitis cronica C con o sin coinfeccion por el VIH

Buenestado-García, Juan; Rubio-Rivas, Manuel; Reñé-Espinet, Josep Maria; Piñol-Felis, Carmen; Egido-García, Ramón; Rubio-Caballero, Manuel.
Med. clín (Ed. impr.) ; 127(15): 561-566, oct. 2006. tab
Artículo en Es | IBECS (España) | ID: ibc-049554

Documentos relacionados

  1. Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics.
  2. Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
  3. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
  4. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
  5. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
  6. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
  7. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
  8. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
  9. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
  10. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.